^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    EGFR (Epidermal growth factor receptor)

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
    2d
    Catalytic Lysine745 targeting strategy in fourth-generation EGFR tyrosine kinase inhibitors to address C797S mutation resistance. (PubMed, Eur J Med Chem)
    The study suggests that hybrid scaffolds combining key pharmacophoric features from Osimertinib and Brigatinib along with Lys745 targeting warheads, could enhance selectivity and potency. Fourth-generation TKIs targeting Lys745 offer a novel therapeutic avenue, potentially overcoming mutation-induced resistance and improving NSCLC treatment outcomes. This approach represents a critical advancement toward durable clinical responses in patients with drug-resistant cancer.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR C797S
    |
    Tagrisso (osimertinib) • Alunbrig (brigatinib)
    2d
    Comparative Kidney Uptake of Nanobody-Based PET Tracers Labeled with Various Fluorine-18-Labeled Prosthetic Groups. (PubMed, Mol Pharm)
    Moreover, the potential substitution of 18F with therapeutic radioisotopes such as 131I or 211At could expand the application of these nanobodies from diagnostics to targeted radionuclide therapy while maintaining a low kidney exposure. These findings have important implications for optimizing nanobody-based radiopharmaceuticals for molecular imaging and targeted radionuclide therapy.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    2d
    Exploring the molecular mechanism of Taohong Siwu decoction in the treatment of non-small-cell lung cancer based on network pharmacology and molecular docking. (PubMed, J Pharm Pharmacol)
    The potential targets and molecular mechanisms of THSWD in the treatment of NSCLC were preliminarily revealed by a comprehensive analysis in this study, which will provide new ideas and methods for the study of the mechanism of traditional Chinese medicine in treating lung cancer.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CCND1 (Cyclin D1) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CDH1 (Cadherin 1) • MAP1LC3A (Microtubule Associated Protein 1 Light Chain 3 Alpha) • MAPK8 (Mitogen-activated protein kinase 8)
    |
    CCND1 expression • CDH1 expression • IL6 expression
    2d
    Case report: Favorable efficacy of combined afatinib and anlotinib treatment in a lung adenocarcinoma patient harboring uncommon EGFR L858M/L861R mutations. (PubMed, Front Pharmacol)
    The patient, now on combination therapy for exceeding 12 months, exhibits further decreased tumor size and a high quality of life. This case underscores the importance of precise molecular diagnosis in guiding therapeutic strategies and provides a valuable reference for clinical decision-making in EGFR-positive NSCLC cases with atypical mutations.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR positive
    |
    Gilotrif (afatinib) • Focus V (anlotinib)
    2d
    A predictive nomogram for EGFR mutation status in lung adenocarcinoma manifesting as ground-glass nodules. (PubMed, J Thorac Dis)
    The DCA showed that when it comes to EGFR mutation status prediction, the nomogram and the radiomics model showed better overall net benefit than the radiographic model. For preoperatively predicting the status of EGFR mutation in lung adenocarcinomas manifesting as GGNs, the CT-based radiomics analysis will be valuable.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    2d
    Prognostic impact of EGFR mutations in T1-4N0M0 lung adenocarcinoma: analyses focus on imaging and pathological features. (PubMed, J Thorac Dis)
    EGFR mutations are associated with a favorable prognosis in nodules with lower IASLC grading or more ground glass opacity (GGO) components. The results were reversed in patients with higher IASLC grading or no GGO component.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR positive
    2d
    Gene targets with therapeutic potential in hepatocellular carcinoma. (PubMed, World J Gastrointest Oncol)
    Fatty acid binding protein 5 is highly expressed in HCC tissues and correlates with key oncogenes, suggesting its potential as a biomarker. Other genes such as guanine monophosphate synthase, cell division cycle associated 5, and epidermal growth factor receptor provide insights into the molecular mechanisms of HCC, offering potential as biomarkers and therapeutic targets.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • STAT3 (Signal Transducer And Activator Of Transcription 3) • FABP5 (Fatty Acid Binding Protein 5)
    2d
    Discover Mutational Differences Between Lung Adenocarcinoma and Lung Squamous Cell Carcinoma and Search for More Effective Biomarkers for Immunotherapy. (PubMed, Cancer Manag Res)
    We observed distinct mutation patterns and clinical factors between LUAD and LUSC, and noted that patients with TMB≥10 and PD-L1≥50% exhibited enhanced immunotherapy effects. Combining TMB≥10 and PD-L1≥50% proved to be a more effective predictor of immunotherapy efficacy.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • KMT2D (Lysine Methyltransferase 2D) • LRP1B (LDL Receptor Related Protein 1B) • KMT2C (Lysine Methyltransferase 2C) • FAT1 (FAT atypical cadherin 1) • RBM10 (RNA Binding Motif Protein 10)
    |
    PD-L1 expression • TP53 mutation • KMT2D mutation • MLL3 mutation
    2d
    A Novel Peroxisome-Related Gene Signature Predicts Breast Cancer Prognosis and Correlates with T Cell Suppression. (PubMed, Breast Cancer (Dove Med Press))
    Drug sensitivity analysis revealed that the PRG high-risk subgroup was sensitive to inhibitors of BCL-2 family proteins (BCL-2, BCL-XL, and MCL1) and other kinases (PLK1, PLK1, BTK, CHDK1, and EGFR). The PRG risk signature serves as a promising biomarker for evaluating peroxisomal activity, prognosis, and responsiveness to immunotherapy in breast cancer.
    Journal • Gene Signature • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BCL2 (B-cell CLL/lymphoma 2) • CD8 (cluster of differentiation 8) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1) • PLK1 (Polo Like Kinase 1) • NOS2 (Nitric Oxide Synthase 2) • ACSL5 (Acyl-CoA Synthetase Long Chain Family Member 5)
    2d
    OST Catalytic Subunit Redundancy Enables Therapeutic Targeting of N-Glycosylation. (PubMed, bioRxiv)
    A mechanistic approach for partial inhibition of N-glycosylation delivers small molecules with anti-tumor activity in EGFR mutant NSCLC.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    2d
    Temporal dynamics of fluorescence and photoacoustic signals of a Cetuximab-IRDye800 conjugate in EGFR-overexpressing tumors. (PubMed, bioRxiv)
    Our data suggests that tumor cell surface binding results in peak PA signal while lysosomal localization and degradation results in a significant drop in PA signal. Our study sheds light on the distinct temporal dynamics of PA and fluorescence signals of Cetuximab-IRDye800 conjugate and we propose that optimizing IRDye800 conjugation to antibodies can further enhance PA signal intensity when timed to precisely to capture IRDye800 in an H-aggregate form.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    2d
    Indian Shot (Canna Indica L). Leaves Provide Valuable Insights into the Management of Inflammation and Other Associated Disorders Offering Health Benefits. (PubMed, J Inflamm Res)
    This research provides valuable insights into the bioactivity evaluation of C. indica, bridging the gap between its chemical composition and diverse biological effects. The findings contribute to the growing body of knowledge in natural product-based drug discovery and underscore the significance of C. indica as a potential source of novel therapeutic agents to treat inflammation and other disease states.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • TNFA (Tumor Necrosis Factor-Alpha)
    2d
    Noninvasive early identification of durable clinical benefit from immune checkpoint inhibition: a prospective multicenter study (NCT04566432). (PubMed, Signal Transduct Target Ther)
    Taken together, these results demonstrate that integrating early changes of ctDNA, normalized bTMB, and the first RECIST response can provide accurate, noninvasive, and early prediction of durable benefits for NSCLC patients treated with ICIs. Further prospective studies are warranted to validate these findings and guide clinical decision-making for optimal immunotherapy in NSCLC patients.
    Clinical • Journal • Checkpoint inhibition • Tumor mutational burden
    |
    EGFR (Epidermal growth factor receptor) • TMB (Tumor Mutational Burden)
    3d
    Molecular pathology of lung adenocarcinomas, EGFR T790M resistance mutation study (PubMed, Magy Onkol)
    Our results were similar to the previous period. The number of rebiopsies was essentially unchanged compared to the 2019-2021 period, which may be the main reason why we were able to identify the mutation in a lower percentage compared to the T790M hit rate described in the literature.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR T790M
    4d
    Association of Oncogene Driver Mutations with Recurrence and Survival in Stage I Nonsmall Cell Lung Cancer. (PubMed, Clin Lung Cancer)
    Oncogene mutations such as KRAS G12V and EGFR may have implications for cancer surveillance strategies and inform future treatment trials of stage I NSCLC.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog)
    |
    TP53 mutation • KRAS mutation • EGFR mutation • PTEN mutation • KRAS G13D • MET mutation • KRAS G12 • KRAS G13
    4d
    Genetic profile in primary tumor tissue of advanced lung adenocarcinoma patients with adrenal metastasis. (PubMed, Cancer Genet)
    EGFR mutations, especially rare variants (G724A, L747P, Q701 L, G719C, V769 L and S768I), exhibited significant enrichment in the non-AM group (P<0.001)...Meanwhile, patients with adrenal metastases harboring ALK or KRAS mutations have a poor prognosis and require more aggressive treatment. The TNF and TGF-β pathways might be associated with adrenal metastasis.
    Journal • BRCA Biomarker • Metastases
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • RET (Ret Proto-Oncogene) • NOTCH1 (Notch 1) • KEAP1 (Kelch Like ECH Associated Protein 1) • LRP1B (LDL Receptor Related Protein 1B) • BRCA (Breast cancer early onset) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    KRAS mutation • ALK mutation • RET mutation • KEAP1 mutation • EGFR S768I • EGFR L747P • EGFR G719C
    4d
    Outcome of osimertinib-treated patients with epidermal growth factor receptor mutation-positive nonsmall cell lung cancer requiring dose reduction: a secondary analysis of the Reiwa study. (PubMed, Jpn J Clin Oncol)
    Many patients require osimertinib dose reduction due to adverse events, but this process does not adversely affect the drug efficacy.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR positive
    |
    Tagrisso (osimertinib)
    4d
    Radiomics based on dual-layer spectral detector CT for predicting EGFR mutation status in non-small cell lung cancer. (PubMed, J Appl Clin Med Phys)
    Nomogram integrating clinical factors and pretreatment DLCT radiomic features can help evaluate the EGFR mutation status of patients with NSCLC in a noninvasive way.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    4d
    Public assistance and survival equality in patients with EGFR mutation-positive lung cancer. (PubMed, Jpn J Clin Oncol)
    Our findings suggest that neither the use of public assistance nor the urbanization level in the residential region significantly impacts the prognosis of Japanese patients with EGFR mutation-positive NSCLC.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    4d
    Persist or resist: Immune checkpoint inhibitors in EGFR-mutated NSCLC. (PubMed, Cancer Sci)
    We further discussed the factors determining the efficacy of ICIs in EGFR-mutated NSCLC patients, the mutation subtypes and microenvironment characteristics of potential responders. More importantly, we provided insights into areas worth further investigation in the future.
    Review • Journal • Checkpoint inhibition • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
    |
    EGFR mutation • EGFR wild-type
    4d
    Potentiating CAR-T-cell function in the immunosuppressive tumor microenvironment by inverting the TGF-β signal. (PubMed, Mol Ther)
    In mice with high-TGF-β solid tumors, our signal-inverted CAR/TB15 T cells effectively treat tumors by blocking TGF-β and repurposing IL-15 stimulative signaling, resulting in enhanced CAR-T-cell persistence and function. As a proof of concept, our study results extend synthetic receptor signaling beyond CAR-directed killing, which could endow adoptively transferred T cells with new functions that overcome major barriers in the treatment of solid tumors by using a chimeric inverted cytokine receptor.
    Journal • CAR T-Cell Therapy
    |
    EGFR (Epidermal growth factor receptor) • TGFB1 (Transforming Growth Factor Beta 1) • IL15 (Interleukin 15)
    5d
    Current status and future prospects of combined immunotherapy and epidermal growth factor receptor inhibitors in head and neck squamous cell carcinoma. (PubMed, Cancer Treat Rev)
    We found that immunotherapy and EGFR inhibitor combination therapy showed promise in treating patients with HNSCC and exhibited safety with acceptable adverse events. This review may provide valuable insights for the future development of treatments and formulation of therapeutic strategies for HNSCC, as well as useful information for the future design of clinical trials.
    Review • Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor)
    5d
    Epidermal growth factor receptor mutations in breast Cancer: Therapeutic challenges and way forward. (PubMed, Bioorg Chem)
    This review highlights the therapeutic approaches, and the challenges encountered in targeting EGFR-specific mutations. It suggests the need to develop more advanced higher-generation inhibitors for use in combinatorial therapy along with chemo-or-immune therapeutics in clinics as a breast cancer treatment strategy against relapse of the disease.
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    5d
    Expression of Concern: Specific Inhibition of Tumor Cells by Oncogenic EGFR Specific Silencing by RNA interference. (PubMed, PLoS One)
    No abstract available
    Journal • Tumor cell
    |
    EGFR (Epidermal growth factor receptor)
    5d
    Optimizing epidermal growth factor receptor-tyrosine kinase inhibitor treatment in lung cancer: a systematic review and meta-analysis of the influence of gastric acid suppressants. (PubMed, Transl Lung Cancer Res)
    Careful consideration is advised when prescribing GASs, including adjusting administration timing, minimizing overlap duration, or opting for H2RAs over PPIs. Further research is needed to optimize treatment protocols, specifically addressing the duration of overlap time, to improve patient outcomes.
    Retrospective data • Review • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    5d
    Prognostic impact of targetable driver alterations in resected early-stage lung cancer. (PubMed, Transl Lung Cancer Res)
    The lack of association between molecular alteration status and recurrence risk prevailed after multivariable adjustment for tumor stage and perioperative treatment (P=0.82 for KRAS G12C mutation and P=0.43 for any other molecular alteration). NSCLC patients with resected tumors that harbor molecular alterations have the same recurrence risk as patients with tumors without molecular alterations if treated with surgery plus chemotherapy when indicated.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase)
    |
    BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • ALK fusion • ALK mutation • KRAS G12
    5d
    EGFR-V834L combined with L858R mutation reduced afatinib sensitivity and associated to early recurrence in lung cancer. (PubMed, Transl Lung Cancer Res)
    The third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib is widely used as a first-line treatment for EGFR-mutated non-small cell lung cancer (NSCLC). In three cases of EGFR-L858R+V834L, other co-mutations, including TP53, CTNNB1, and RB1, were detected either before or after afatinib resistance. These results suggested that V834L cooperates with other coexisting mutations to influence the therapeutic efficacy of EGFR-TKIs.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    |
    TP53 mutation • EGFR mutation • EGFR L858R • EGFR T790M • EGFR V834L
    |
    Tagrisso (osimertinib) • Gilotrif (afatinib)
    5d
    Circulating tumor cells are associated with lung cancer subtypes: a large-scale retrospective study. (PubMed, Transl Lung Cancer Res)
    We conducted a comprehensive analysis of the tumor properties, radiological features, and genomic characteristics that are significantly associated with CTCs in different lung cancer subtypes. This study helps elucidate the formation mechanism and relevant major regulation molecules of CTCs.
    Retrospective data • Journal • Circulating tumor cells • Tumor cell
    |
    EGFR (Epidermal growth factor receptor) • CD68 (CD68 Molecule)
    |
    EGFR mutation
    |
    CELLSEARCH®
    5d
    EGFR exon 20 insertion mutation and MET exon 14 skipping mutation in non-small cell lung cancer: a scoping review in the Chinese population. (PubMed, Transl Lung Cancer Res)
    Further large-scale studies are needed to establish links between these mutations and clinical features at baseline and following treatment. Furthermore, moving forward, the development of novel drugs will be essential to fulfill the clinical unmet needs.
    Review • Journal • EGFR exon 20
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR exon 20 insertion • MET exon 14 mutation • MET mutation
    5d
    The Cdk inhibitor dinaciclib as a promising anti-tumorigenic agent in biliary tract cancer. (PubMed, Cancer Biol Ther)
    Additionally, dinaciclib affects different cell growth regulators like EGFR and STAT3 on gene and protein level, thus decreasing tumor growth. In summary, our study indicates that dinaciclib acts as a promising anti-tumorigenic agent in 2D and 3D in vitro BTC models and thus encourages further investigation.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • MCL1 (Myeloid cell leukemia 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CASP3 (Caspase 3) • CASP7 (Caspase 7) • CDK1 (Cyclin-dependent kinase 1)
    |
    MCL1 expression
    |
    dinaciclib (MK-7965)
    5d
    Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients with EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19) (clinicaltrials.gov)
    P1, N=25, Completed, Dizal Pharmaceuticals | Recruiting --> Completed | Trial primary completion date: Aug 2024 --> May 2024
    Trial completion • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR mutation • HER-2 mutation
    |
    sunvozertinib (DZD9008)
    6d
    Topological radiogenomics based on persistent lifetime images for identification of epidermal growth factor receptor mutation in patients with non-small cell lung tumors. (PubMed, Comput Biol Med)
    The best radiogenomic approaches with the highest AUC were the random forest model trained with the Betti number (BN) map features (AUC = 0.984) in the internal test and the adapting boosting model trained with the BN map features (AUC = 0.717) in the external test. PLT features can be used as radiogenomic imaging biomarkers for the identification of EGFR mutation status in patients with NSCLC.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    6d
    Discovery of a Novel Mutant-Selective Epidermal Growth Factor Receptor Inhibitor Using an In Silico Enabled Drug Discovery Platform. (PubMed, J Med Chem)
    Compound 31 inhibited EGFR L858R/T790M/C797S in biochemical assays with a Ki = 2.1 nM and EGFR del19/T790M/C797S in a Ba/F3 cellular assay with an IC50 = 56.9 nM. The deuterated analogue of 31 (38) demonstrated dose-dependent tumor growth inhibition in a Ba/F3 EGFR del19/T790M/C797S CDX model by 47% at 50 mg/kg BID and 92% at 100 mg/kg BID.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR C797S
    6d
    ERBB2/ERBB3-mutated S100/SOX10-positive uterine sarcoma: something new. (PubMed, Virchows Arch)
    The authors review the sparse literature on molecular-genetic aberrations involving the epidermal growth factor receptor family of receptor tyrosine kinases (ERBB1/EGFR, ERBB2, ERBB3, and ERBB4) in uterine mesenchymal tumors, a review that suggests that such tumors may be pathologically heterogeneous. The potential clinical significance of demonstrating a targetable ERBB2/ERBB3 tyrosine kinase mutation or other EGFR family aberrations, as well as its distinctive pathologic profile, supports the segregation of the tumor reported herein as a distinct and emerging entity.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase) • PGR (Progesterone receptor) • FGFR1 (Fibroblast growth factor receptor 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • NF1 (Neurofibromin 1) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • ATRX (ATRX Chromatin Remodeler) • ERBB4 (erb-b2 receptor tyrosine kinase 4) • CD34 (CD34 molecule) • NCAM1 (Neural cell adhesion molecule 1) • SOX10 (SRY-Box 10) • CD68 (CD68 Molecule) • MME (Membrane Metalloendopeptidase) • PRAME (Preferentially Expressed Antigen In Melanoma) • MLANA (Melan-A) • NTRK (Neurotrophic receptor tyrosine kinase) • PDGFB (Platelet Derived Growth Factor Subunit B) • STAT6 (Signal transducer and activator of transcription 6) • MITF (Melanocyte Inducing Transcription Factor)
    |
    EGFR mutation • HER-2 mutation • CDKN2A deletion • ATRX mutation • ERBB3 mutation • NF1 deletion
    6d
    EGFR and MUC1 as dual-TAA drug targets for lung cancer and colorectal cancer. (PubMed, Front Oncol)
    Single-cell RNA, bulk RNA and IHC data demonstrated the high expression levels and co-expression patterns of EGFR and MUC1 in tumors but not normal tissues. Therefore, it is a promising TAA combination for therapeutic targeting which could enhance on-tumor efficacy while reducing off-tumor toxicity.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • MUC1 (Mucin 1)
    |
    EGFR expression • MUC1 expression • MUC1 expression + EGFR expression
    6d
    A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) (clinicaltrials.gov)
    P1, N=230, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Feb 2025 --> Jun 2025 | Trial primary completion date: Feb 2025 --> Jun 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    Keytruda (pembrolizumab) • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • MK-0482
    6d
    First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=72, Terminated, Navire Pharma Inc., a BridgeBio company | N=130 --> 72 | Trial completion date: Feb 2025 --> Jul 2024 | Active, not recruiting --> Terminated; Business decision
    Enrollment change • Trial completion date • Trial termination • Metastases
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
    |
    KRAS mutation • EGFR mutation • KRAS G12C • KRAS G12
    |
    BMS-986466
    6d
    Pembrolizumab with Standard Cytotoxic Chemotherapy in Treatment Naive NSCLC Patients with Asymptomatic Brain Metastases (clinicaltrials.gov)
    P2, N=13, Completed, Samsung Medical Center | Recruiting --> Completed | N=50 --> 13 | Trial completion date: Feb 2026 --> Dec 2024 | Trial primary completion date: Sep 2025 --> Jun 2024
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed
    6d
    FINN: A Study in Participants With First-Line Nivolumab Plus Ipilimumb Therapy Combined With Two Cycles of Chemotherapy for Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P=N/A, N=825, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    7d
    Self-improving generative foundation model for synthetic medical image generation and clinical applications. (PubMed, Nat Med)
    Using a large retrospective simulation analysis, we demonstrate MINIM's clinical potential by accurately identifying targeted therapy-sensitive EGFR mutations using lung cancer computed tomography images, which could potentially lead to improved 5-year survival rates. Although these results are promising, further validation and refinement in more diverse and prospective settings would greatly enhance the model's generalizability and robustness.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • EGFR mutation
    7d
    Ivonescimab Plus Chemotherapy in Patients With EGFR Variant Non-Small Cell Lung Cancer. (PubMed, JAMA)
    No abstract available
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    Yidafan (ivonescimab)
    7d
    Ivonescimab Plus Chemotherapy in Patients With EGFR Variant Non-Small Cell Lung Cancer-Reply. (PubMed, JAMA)
    No abstract available
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    Yidafan (ivonescimab)